Description

WashU Medicine Mallinckrodt Institute of Radiology has an opening for its one-year fellowship in Nuclear Oncology (Molecular Imaging and Theranostics) for 2026-2027. 

The nuclear medicine faculty at WashU Medicine includes 15 MD and MD/PhD members and 2 PhD members.  Nuclear medicine instrumentation includes two clinical PET/CT scanners (one of which features a larger axial field of view), five SPECT/CT scanners, and seven conventional gamma cameras. We have an on-site Cyclotron Facility and extensive radiochemistry laboratories that provide routine radiopharmaceuticals for clinical use and novel radiopharmaceuticals for research studies. Our Center of Clinical Imaging Research (CCIR) is equipped with two PET/CT and 1 PET/MRI scanners, as well as two 3-Telsa MRI scanners. Our Center for Clinical Theranostics Research (CCTR) is equipped with four outpatient radiopharmaceutical therapy bays, dedicated clinical examination rooms, and a hot lab with access to GMP radiopharmaceuticals. We also have inpatient lead shielded rooms for high-dose radiopharmaceutical therapy. Dosimetry for radiopharmaceutical therapy is routinely performed in selected patients.

The faculty of the Division of Nuclear Medicine is involved in a range of research activities including:

Clinical trials with investigational therapeutic radiopharmaceuticals (neuroendocrine tumors and prostate cancer, as well as other solid tumors, such as neuroblastoma, breast and gastric cancers) and PET/CT with novel radiopharmaceuticals (such as imaging agents targeting progesterone-receptors, PARP, CCR2, VLA-4, PSMA). 

Requirements

The applicant should have completed training in Nuclear Medicine and be either ABNM-eligible or certified, and be interested in participating in research projects. The fellowship, which is not ACGME-accredited, will provide extensive experience in oncologic clinical PET/CT, SPECT/CT, and nuclear medicine therapy (theranostic). Learning is enhanced through close collaboration with faculty in Radiation Oncology and Medical Oncology. Additionally, there will be attendance/participation in multidisciplinary tumor boards, as well as lectures, journal clubs, and involvement in the daily workflow of our imaging and theranostic centers. Research opportunities exist with novel diagnostic and therapeutic radiopharmaceuticals.